18.02.2014 • News

Clariant Said to Plan Exit from ASK Joint Venture With Ashland

Clariant is seeking to unload its stake in ASK Chemicals, a 50:50 joint venture with U.S.-based chemical producer Ashland, according to unconfirmed reports.

People familiar with the transaction told the news agency Reuters that several companies are interested, including private equity investor Sun Capital. Offers would be accepted until the end of February, the reports said.

Based at Hilden, near Düsseldorf, Germany, the company with 1,800 employees produces binding agents and additives for the foundry sector. Clariant has operative control.

Analysts said ASK could be valued at six to seven times the expected 2013 EBITDA of €40 million, which would give the chemical producer an enterprise value of €240-280 million.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.